Cytovale
Latest round
- Series D
Last raised
- Oct 2024
Total raised
- $238M
Investors
- 10
About Cytovale
Based in the US, Cytovale, Inc.Cytovale, Inc. specializes in developing and commercializing diagnostic tools, particularly the IntelliSep Sepsis Test.Cytovale specializes in the development and commercialization of innovative medical diagnostics, focusing primarily on their flagship product, the IntelliSep Sepsis Test. This FDA-cleared in vitro diagnostic test operates on a proprietary medical device designed to rapidly risk-stratify adult patients presenting with signs and symptoms of infection in emergency department settings. The IntelliSep test analyzes the biomechanical properties of white blood cells to assess immune activation and provides critical test results in approximately 8 minutes, enabling healthcare professionals to identify the likelihood of sepsis with organ dysfunction occurring within three days. The primary end users of this solution are healthcare providers, including physicians, nurses, and laboratorians, who utilize the technology to improve patient outcomes by facilitating timely interventions.Cytovale generates revenue through direct sales of the IntelliSep Sepsis Test and its accompanying medical device to healthcare institutions, such as hospitals and emergency departments. The transaction structure is based on a business-to-business (B2B) model, where healthcare providers purchase the test kits and devices for clinical use. This involves upfront costs associated with acquiring the IntelliSep system and consumables necessary for testing. While specific pricing details are not disclosed, the sales model indicates that healthcare facilities invest in these diagnostic tools to enhance their capabilities in sepsis detection and treatment.In October 2024, Cytovale, Inc. By targeting new geographic regions for growth, Cytovale aims to enhance its presence in the medical diagnostics market.
Who invested in Cytovale
10 investors across 6 rounds
See all investors in Cytovale
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cytovale
Who invested in Cytovale?
Cytovale has 10 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cytovale raised?
Cytovale has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Cytovale last raise money?
Cytovale's most recent round on record is a Series D, in Oct 2024.
What does Cytovale do?
Based in the US, Cytovale, Inc.
Where is Cytovale headquartered?
Cytovale is headquartered in South San Francisco, US.
Which VCs invest in companies like Cytovale?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Cytovale's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Cytovale? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.